Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Valsartan | Research

Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway

Authors: Congfeng Xu, Ning Zhang, Hong Yuan, Liren Wang, Yonghong Li

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Aims

To explore the role and mechanism of Notch signaling and ERK1/2 pathway in the inhibitory effect of sacubitril/valsartan on the proliferation of vascular smooth muscle cells (VSMCs).

Main methods

Human aortic vascular smooth muscle cells (HA-VSMCs) were cultured in vitro. The proliferating VSMCs were divided into three groups as control group, Ang II group and Ang II + sacubitril/valsartan group. Cell proliferation and migration were detected by CCK8 and scratch test respectively. The mRNA and protein expression of PCNA, MMP-9, Notch1 and Jagged-1 were detected by qRT-PCR and Western blot respectively. The p-ERK1/2 expression was detected by Western blot.

Key findings

Compared with the control group, proliferation and migration of VSMCs and the expression of PCNA, MMP-9, Notch1, Jagged-1 and p-ERK1/2 was increased in Ang II group. Sacubitril/valsartan significantly reduced the proliferation and migration. Additionally, pretreatment with sacubitril/valsartan reduced the PCNA, MMP-9, Notch1, Jagged-1 and p-ERK1/2 expression.

Available only for authorised users

Roth G A, Mensah G A, Johnson C O, et al. Global Burden of Cardiovascular diseases and Risk factors, 1990–2019: Update from the GBD 2019 study [J]. J Am Coll Cardiol. 2020;76(25):2982–3021.CrossRefPubMedPubMedCentral

Giustino G, Colombo A, Camaj A, et al. Coronary In-Stent restenosis: JACC state-of-the-art review [J]. J Am Coll Cardiol. 2022;80(4):348–72.CrossRefPubMed

Zhao Y, Zang G, Yin T, et al. A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway [J]. Bioactive Mater. 2021;6(2):375–85.CrossRef

Maguire E M Xiaoq. Noncoding RNAs in vascular smooth muscle cell function and neointimal hyperplasia [J]. 2020, 287(24): 5260–83.

Sprinzak D, Blacklow SC. Biophysics of Notch Signaling [J]. Annual Rev Biophys, 2021, 50(157 – 89.

VáZquez-Ulloa E, Lin K L, Lizano M, et al. Reversible and bidirectional signaling of notch ligands [J]. Crit Rev Biochem Mol Biol. 2022;57(4):377–98.CrossRefPubMed

T Friedrich F, Ferrante. Notch-dependent and -independent functions of transcription factor RBPJ. J. 2022;50(14):7925–37.

Dong M, Liu X, Evert K, et al. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model [J]. Volume 9. Cell death & disease; 2018. p. 31. 2.

Del Gaudio F, Liu D, Lendahl U. Notch signalling in healthy and diseased vasculature [J]. 2022, 12(4): 220004.

10.

Nakamura A, Goto Y. Shedding light on developmental ERK signaling with genetically encoded biosensors [J]. 2021, 148(18).

11.

Degirmenci U, Wang M. Hu J. Targeting aberrant RAS/RAF/MEK/ERK Signaling for Cancer therapy [J]. Cells, 2020, 9(1).

12.

Guo S, Zhou Y, Xie X. Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, 155(113775.

13.

Murphy S P, Prescott M F Camachoa, et al. Atrial Natriuretic Peptide and treatment with Sacubitril/Valsartan in heart failure with reduced ejection fraction [J]. JACC Heart Fail. 2021;9(2):127–36.CrossRefPubMed

14.

Sarzani R, Allevi M, Di Pentima C et al. Role of Cardiac natriuretic peptides in Heart structure and function [J]. Int J Mol Sci, 2022, 23(22).

15.

Sarzani R, Salvi F, Dessì-Fulgheri P, et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans [J]. J Hypertens. 2008;26(5):831–43.CrossRefPubMed

16.

D’Elia E, Iacovoni A, Vaduganathan M, et al. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides [J]. Eur J Heart Fail. 2017;19(6):710–7.CrossRefPubMed

17.

Liao H, Gong J, Zhang W et al. Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2 [J]. Journal of Huazhong University of Science and Technology Medical sciences = Hua Zhong Ke Ji Da Xue Xue bao Yi Xue Ying De Wen ban = Huazhong keji daxue xuebao yixue yingdewen ban, 2012, 32(1): 31–5.

18.

Chaumais M C, Djessas M R A, Thuillet R, et al. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension [J]. Cardiovascular Res. 2021;117(5):1391–401.CrossRef

19.

Gaidai O, Cao Y. Curr Probl Cardiol. 2023;48(5):101622. LOGINOV S. Global Cardiovascular Diseases Death Rate Prediction [J].

20.

Hoole S P Bambroughp. Recent advances in percutaneous coronary intervention [J]. Heart. 2020;106(18):1380–6.CrossRefPubMed

21.

Colleran R, Kastrati A. Percutaneous coronary intervention: balloons, stents and scaffolds [J]. Clin Res Cardiology: Official J German Cardiac Soc. 2018;107(Suppl 2):55–63.CrossRef

22.

Zong J, He Q, Liu Y et al. Advances in the development of biodegradable coronary stents: A translational perspective [J]. Materials today Bio, 2022, 16(100368.

23.

Wang D, Uhrin P, Mocan A, et al. Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways [J]. Biotechnol Adv. 2018;36(6):1586–607.CrossRefPubMed

24.

Ma W, Wei D, Li X et al. CircPCNX promotes PDGF-BB-Induced Proliferation and Migration of Human aortic vascular smooth muscle cells through regulating miR-1278/DNMT1 Axis [J]. 2022.

25.

Jakubiak G K., Pawlas N. Pathogenesis and clinical significance of In-Stent restenosis in patients with diabetes [J]. 2021, 18(22).

26.

Grootaert M O J, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment [J]. 2021, 117(11): 2326–39.

27.

He Z, Wang G, Wu J et al. The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, 139(111667.

28.

Ristori T, Stassen O, Sahlgren C M, et al. Lateral induction limits the impact of cell connectivity on notch signaling in arterial walls [J]. Int J Numer Methods Biomed Eng. 2020;36(4):e3323.MathSciNetCrossRef

29.

Meester J A N, Verstraeten A, Alaerts M, et al. Overlapping but distinct roles for NOTCH receptors in human cardiovascular disease [J]. Clin Genet. 2019;95(1):85–94.CrossRefPubMed

30.

Chiarini A, Onorati F, Marconi M, et al. Studies on sporadic non-syndromic thoracic aortic aneurysms: 1. Deregulation of Jagged/Notch 1 homeostasis and selection of synthetic/secretor phenotype smooth muscle cells [J]. Eur J Prev Cardiol. 2018;25(1suppl):42–50.CrossRefPubMed

31.

Li Y, Takeshita K, Liu P Y, et al. Smooth muscle Notch1 mediates neointimal formation after vascular injury [J]. Circulation. 2009;119(20):2686–92.CrossRefPubMedPubMedCentral

32.

Dong C X Maleckic. Molecular mechanisms in genetic aortopathy-signaling pathways and potential interventions [J]. 2023, 24(2).

33.

Maik-Rachline G, Hacohen-Lev-Ran A, Seger R, Nuclear ERK. Mechanism of translocation, substrates, and role in Cancer [J]. Int J Mol Sci, 2019, 20(5).

34.

Guo YJ, Pan W W, Liu S B, et al. ERK/MAPK signalling pathway and tumorigenesis [J]. Experimental Therapeutic Med. 2020;19(3):1997–2007.

35.

Shi L, Ji Y, Jiang X et al. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways [J]. Cardiovascular diabetology, 2015, 14(18.

36.

Jain M, DEV R, Doddapattar P et al. Integrin α9 regulates smooth muscle cell phenotype switching and vascular remodeling [J]. JCI Insight, 2021, 6(10).

37.

Iacoviello M. Palazzuoli A. Recent advances in pharmacological treatment of heart failure [J]. 2021, 51(11): e13624.

38.

González-Magaña A, Blanco F J. Human PCNA, Structure. Function Interact [J] Biomolecules, 2020, 10(4).

39.

Mondal S, Adhikari N, Banerjee S et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview [J]. European journal of medicinal chemistry, 2020, 194(112260.

40.

Song JB, Shen J, Fan J, et al. Effects of a Matrix metalloproteinase inhibitor-eluting stent on In-Stent restenosis [J]. Med Sci Monitor: Int Med J Experimental Clin Res. 2020;26:e922556.CrossRef

41.

Li LJ, Chang P M, Li C H. FAS receptor regulates NOTCH activity through ERK-JAG1 axis activation and controls oral cancer stemness ability and pulmonary metastasis [J]. 2022, 8(1): 101.

42.

Frismantiene A, Philippova M, Erne P, et al. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity [J]. Cell Signal. 2018;52:48–64.CrossRefPubMed

Title: Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway
Authors: Congfeng Xu
Ning Zhang
Hong Yuan
Liren Wang
Yonghong Li
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Valsartan
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-024-03764-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sacubitril/valsartan inhibits the proliferation of vascular smooth muscle cells through notch signaling and ERK1/2 pathway

Abstract

Aims

Main methods

Key findings

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Main methods

Key findings

Please log in to get access to this content

Other articles of this Issue 1/2024

Rationale and design of the SPRING trail: effectivity and safety of Pfo closuRe vs medIcine in alleviatiNg migraine, a multicenter, randomized and open-label trail

Circulating trimethylamine N-oxide is correlated with high coronary artery atherosclerotic burden in individuals with newly diagnosed coronary heart disease

A national perspective on cardiovascular diseases in Saudi Arabia

Correction: Days alive and out of hospital for adult female and male cardiac surgery patients: a population-based cohort study

The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis

Long term all-cause mortality after myocardial infarction with non-obstructed vs obstructed coronary artery disease: a meta-analysis of adjusted data

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page